ARROS-1

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing

Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.

bySrinath

April 21, 2026

Representative image of a laboratory research setting used to illustrate Nuvalent’s AACR 2026 zidesamtinib update in ROS1-positive non-small cell lung cancer, including focus on brain penetration, resistance mutations, and next-line treatment potential.

Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data

Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.

bySrinath

April 19, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing

Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?